Skip to content

8 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Association of Chronic Vascular Complications of Diabetes With Cardiovascular Autonomic Neuropathy: The Silesia Diabetes-Heart Project.

BACKGROUND Cardiovascular autonomic neuropathy (CAN) is a serious but frequently underdiagnosed complication of diabetes mellitus (DM). Increasing evidence suggests that CAN may coexist with other diabetes-related complications implicating the need for comprehensive screening and holistic risk assessment in people with...

Paweł Ignacy, Krzysztof Irlik, Martyna Gut-Misiaga et al. · 0 citations
Open access Oct 2026

Reduced Risk of MASLD and Cardiometabolic Disease Following Renal Denervation Therapy in Patients With Resistant Hypertension.

INTRODUCTION Autonomic dysfunction increases the risk of cardio-kidney-metabolic (CKM) syndrome including metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes (T2D), cardiovascular disease (CVD) and chronic kidney disease (CKD). Renal denervation reduces renal sympathetic nerve activity and...

A. Henney, M. Anson, David R. Riley et al. · 0 citations
Review Oct 2026

The use of glucagon-like peptide-1 agonists as a treatment for obesity in older people: risks and benefits.

PURPOSE OF REVIEW Obesity is an increasingly important health problem in older adults (≥65 years) and is associated with osteoarthritis, impaired mobility, reduced quality of life, cardiovascular disease, and other age-related comorbidities. This narrative review summarizes the current evidence regarding the benefits a...

M. Kaşkal, U. Alam, Gregory Y. H. Lip · 0 citations
Open access Oct 2026

Cardiovascular–kidney–metabolic risk stratification and cardiorenal outcomes with SGLT2 inhibitors versus GLP-1 receptor agonists in type 2 diabetes: a global federated network study

A consistent cardiorenal benefit pattern was observed across low, moderate and high CKM strata, with SGLT2i reducing renal outcomes and GLP-1RA conferring greater cardiovascular protection.

C. Wang, A. Askarinejad, Y. Chen et al. · 0 citations
Open access Oct 2026

Preconception incretin therapy reduces pregnancy and cardiometabolic outcomes in polycystic ovary syndrome.

Pre-conception GLP-1/GIP RA use in women with PCOS/PMOS was associated with lower risks of adverse pregnancy outcomes and cardiometabolic disease compared with metformin, consistent with potential benefits of pre-conception metabolic optimisation.

A. Henney, Phoebe J. Holmes, David R. Riley et al. · 0 citations
Open access Aug 2026

Increased risk of steatotic liver disease, major adverse liver outcomes, cardiovascular events and mortality in pheochromocytoma: a model of chronically elevated sympathetic tone.

BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally, yet the contribution of autonomic dysfunction to its progression remains incompletely understood. Pheochromocytoma and paraganglioma (PPGL), characterised by excessive catecholamine production,...

A. Henney, A. S. Davison, U. Alam et al. · 0 citations
Review Open access Aug 2026

What Do We Know About Pain Pathways in Diabetic Peripheral Neuropathy? A Contemporary Narrative Review.

PURPOSE Diabetic peripheral neuropathy (DPN) affects up to 50% of individuals with diabetes mellitus and remains one of the most prevalent and disabling chronic complications of the disease. Approximately one-third develop painful DPN (pDPN), characterized by spontaneous burning pain, electric-shock sensations, allodyn...

Paweł Ignacy, Martyna Gut-Misiaga, Aleksandra Gil et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.